Biotest Aktiengesellschaft Performance
| BIESFDelisted Stock | USD 32.00 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Biotest Aktiengesellscha are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Biotest Aktiengesellschaft has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Biotest Aktiengesellscha is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 71.3 M | |
| Total Cashflows From Investing Activities | -23.4 M |
Biotest |
Biotest Aktiengesellscha Relative Risk vs. Return Landscape
If you would invest 3,200 in Biotest Aktiengesellschaft on September 30, 2025 and sell it today you would earn a total of 0.00 from holding Biotest Aktiengesellschaft or generate 0.0% return on investment over 90 days. Biotest Aktiengesellschaft is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Biotest, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Biotest Aktiengesellscha Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biotest Aktiengesellscha's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Biotest Aktiengesellschaft, and traders can use it to determine the average amount a Biotest Aktiengesellscha's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| BIESF |
Based on monthly moving average Biotest Aktiengesellscha is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biotest Aktiengesellscha by adding Biotest Aktiengesellscha to a well-diversified portfolio.
Biotest Aktiengesellscha Fundamentals Growth
Biotest Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Biotest Aktiengesellscha, and Biotest Aktiengesellscha fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biotest Pink Sheet performance.
| Return On Equity | -0.18 | |||
| Return On Asset | -0.0331 | |||
| Profit Margin | (0.14) % | |||
| Operating Margin | (0.12) % | |||
| Current Valuation | 2.01 B | |||
| Shares Outstanding | 19.79 M | |||
| Price To Earning | 4.78 X | |||
| Price To Book | 3.99 X | |||
| Price To Sales | 3.24 X | |||
| Revenue | 515.6 M | |||
| EBITDA | (18.3 M) | |||
| Cash And Equivalents | 79.2 M | |||
| Cash Per Share | 2.04 X | |||
| Total Debt | 473.4 M | |||
| Debt To Equity | 1.23 % | |||
| Book Value Per Share | 8.90 X | |||
| Cash Flow From Operations | 33.9 M | |||
| Earnings Per Share | (1.45) X | |||
| Total Asset | 1.1 B | |||
About Biotest Aktiengesellscha Performance
By analyzing Biotest Aktiengesellscha's fundamental ratios, stakeholders can gain valuable insights into Biotest Aktiengesellscha's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biotest Aktiengesellscha has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biotest Aktiengesellscha has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. As of January 4, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A. Biotest Ag operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1928 people.Things to note about Biotest Aktiengesellscha performance evaluation
Checking the ongoing alerts about Biotest Aktiengesellscha for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Biotest Aktiengesellscha help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biotest Aktiengesellscha is not yet fully synchronised with the market data | |
| Biotest Aktiengesellscha has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 515.6 M. Net Loss for the year was (63.4 M) with profit before overhead, payroll, taxes, and interest of 80.7 M. |
- Analyzing Biotest Aktiengesellscha's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biotest Aktiengesellscha's stock is overvalued or undervalued compared to its peers.
- Examining Biotest Aktiengesellscha's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biotest Aktiengesellscha's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biotest Aktiengesellscha's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biotest Aktiengesellscha's pink sheet. These opinions can provide insight into Biotest Aktiengesellscha's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Biotest Pink Sheet
If you are still planning to invest in Biotest Aktiengesellscha check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biotest Aktiengesellscha's history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |